NASDAQ: RNAZ
Transcode Therapeutics Inc Stock Ownership - Who owns Transcode Therapeutics?

Insider buying vs selling

Have Transcode Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when RNAZ insiders and whales buy or sell their stock.

RNAZ Shareholders

What type of owners hold Transcode Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Zdravka Medarova6.65%1,552,785$670.80kInsider
Anna Moore6.65%1,552,785$670.80kInsider
Robert Michael Dudley0.77%180,262$77.87kInsider
Philippe Calais0.55%127,377$55.03kInsider
Thomas A. Fitzgerald0.24%56,318$24.33kInsider
Ubs Group Ag0.04%8,676$3.75kInstitution
Tower Research Capital LLC Trc0.00%926$400.03Institution
Morgan Stanley0.00%304$131.33Institution
Bank Of America Corp0.00%4$1.73Institution
Concourse Financial Group Securities Inc0.00%0$0.00Institution

1 of 1

RNAZ vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RNAZ0.04%14.86%
ACXP6.40%11.67%Net Buying
APRE3.38%96.62%Net BuyingNet Buying
CYCN11.83%88.17%Net SellingNet Buying
KPRX9.34%90.66%Net Buying

Transcode Therapeutics Stock Ownership FAQ

Who owns Transcode Therapeutics?

Transcode Therapeutics (NASDAQ: RNAZ) is owned by 0.04% institutional shareholders, 14.86% Transcode Therapeutics insiders, and 85.09% retail investors. Zdravka Medarova is the largest individual Transcode Therapeutics shareholder, owning 1.55M shares representing 6.65% of the company. Zdravka Medarova's Transcode Therapeutics shares are currently valued at $631.98k.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.